Kim et al. reported that in a large cohort of diabetic patients, those receiving DPP-4 inhibitor combination therapy had a reduced risk of autoimmune diseases—including IBD—compared to those receiving non-DPP-4 inhibitor combination therapy [201]. Here, DPP4 is linked to irritable bowel syndrome.